JOP20200034A1 - تركيبة للتنشيط المتحكم فيه للمبيض - Google Patents

تركيبة للتنشيط المتحكم فيه للمبيض

Info

Publication number
JOP20200034A1
JOP20200034A1 JOP/2020/0034A JOP20200034A JOP20200034A1 JO P20200034 A1 JOP20200034 A1 JO P20200034A1 JO P20200034 A JOP20200034 A JO P20200034A JO P20200034 A1 JOP20200034 A1 JO P20200034A1
Authority
JO
Jordan
Prior art keywords
composition
ovarian stimulation
controlled ovarian
controlled
stimulation
Prior art date
Application number
JOP/2020/0034A
Other languages
English (en)
Inventor
Saez Joan-Carles Arce
Bjarke Mirner Klein
Lisbeth Helmgaard
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of JOP20200034A1 publication Critical patent/JOP20200034A1/ar
Application granted granted Critical
Publication of JOP20200034B1 publication Critical patent/JOP20200034B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

غير متوفر
JOJO/P/2020/0034A 2017-09-01 2020-02-13 تركيبة للتنشيط المتحكم فيه للمبيض JOP20200034B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17189119 2017-09-01
PCT/EP2018/073442 WO2019043143A1 (en) 2017-09-01 2018-08-31 COMPOSITION FOR CONTROLLED OVARIAN STIMULATION

Publications (2)

Publication Number Publication Date
JOP20200034A1 true JOP20200034A1 (ar) 2020-02-13
JOP20200034B1 JOP20200034B1 (ar) 2024-04-18

Family

ID=59772482

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2020/0034A JOP20200034B1 (ar) 2017-09-01 2020-02-13 تركيبة للتنشيط المتحكم فيه للمبيض

Country Status (32)

Country Link
US (2) US11744879B2 (ar)
EP (3) EP3675894B1 (ar)
JP (2) JP6856819B2 (ar)
KR (2) KR20250078595A (ar)
CN (2) CN111050787A (ar)
AR (1) AR112541A1 (ar)
AU (1) AU2018326556B2 (ar)
BR (1) BR112020003379A2 (ar)
CA (1) CA3073624A1 (ar)
CL (1) CL2020000482A1 (ar)
DK (2) DK3675894T3 (ar)
EA (1) EA202090480A1 (ar)
ES (2) ES2989511T3 (ar)
FI (1) FI3973982T3 (ar)
HR (2) HRP20241171T1 (ar)
HU (2) HUE068024T2 (ar)
IL (1) IL272763B2 (ar)
JO (1) JOP20200034B1 (ar)
LT (2) LT3675894T (ar)
MA (2) MA56224B1 (ar)
MD (2) MD3675894T2 (ar)
MX (2) MX2020002235A (ar)
MY (1) MY200791A (ar)
PH (1) PH12020500404A1 (ar)
PL (2) PL3675894T3 (ar)
PT (2) PT3973982T (ar)
RS (2) RS65945B1 (ar)
SG (1) SG11202003840QA (ar)
SI (2) SI3675894T1 (ar)
TW (1) TWI749255B (ar)
UA (1) UA126869C2 (ar)
WO (1) WO2019043143A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
TW202237173A (zh) * 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2397680A1 (en) * 2000-01-27 2001-08-02 Applied Research Systems Ars Holding N.V. Use of fsh for treating infertility
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
ES2494928T3 (es) * 2007-09-21 2014-09-16 Pharmabrand S.A. Composición que comprende polisacáridos mucilaginosos derivados de Aloe barbadensis combinados con liposomas, procedimiento para la obtención de los mismos y su uso como protector solar, un agente antiacné, un regenerador epidérmico y un hidratante
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
WO2011089602A2 (en) * 2010-01-21 2011-07-28 Ramot At Tel-Aviv University Ltd. Aloe-emodin derivatives and use thereof for the treatment of cancer
PT2621517E (pt) 2010-09-29 2015-10-16 Ferring Bv Composição para uso no tratamento da infertilidade
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
MX2016013449A (es) * 2014-04-18 2017-05-04 Glycotope Gmbh Hiperestimulacion ovarica controlada con la hormona estimuladora folicular humana recombinante mejorada.
PL3261661T3 (pl) 2015-02-26 2024-03-25 Ferring B.V. Menotropina do leczenia niepłodności
EP3283097B1 (en) 2015-04-17 2020-02-12 Ferring B.V. Fsh for treatment of infertility
SI3286209T1 (sl) 2015-04-24 2021-01-29 Ferring Bv Postopek izdelave gonadotropina
MY179524A (en) 2015-06-26 2020-11-10 Ferring Bv Methods of purification and/or viral inactivation
HUE071268T2 (hu) 2018-04-30 2025-08-28 Ferring Bv Készítmény szabályozott petefészek-stimuláláshoz
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法

Also Published As

Publication number Publication date
MD3675894T2 (ro) 2022-03-31
RS65945B1 (sr) 2024-10-31
AR112541A1 (es) 2019-11-06
KR20200045543A (ko) 2020-05-04
CL2020000482A1 (es) 2020-06-26
HRP20241171T1 (hr) 2024-11-22
TW201919687A (zh) 2019-06-01
US11744879B2 (en) 2023-09-05
SI3675894T1 (sl) 2022-01-31
EA202090480A1 (ru) 2020-07-20
IL272763B1 (en) 2023-10-01
MX2020002235A (es) 2020-07-20
PT3675894T (pt) 2022-01-25
TWI749255B (zh) 2021-12-11
FI3973982T3 (fi) 2024-09-23
US20200197493A1 (en) 2020-06-25
SI3973982T1 (sl) 2024-10-30
JP7373479B2 (ja) 2023-11-02
MA56224B1 (fr) 2024-09-30
US20240024424A1 (en) 2024-01-25
LT3675894T (lt) 2021-12-10
PL3675894T3 (pl) 2022-02-21
MD3973982T2 (ro) 2024-11-30
MA50034A (fr) 2021-05-12
EP3973982B1 (en) 2024-07-31
ES2904787T3 (es) 2022-04-06
DK3675894T3 (da) 2022-01-24
MA56224A (fr) 2022-04-20
MX2024009224A (es) 2024-08-06
JP2021046398A (ja) 2021-03-25
HUE056726T2 (hu) 2022-03-28
AU2018326556A1 (en) 2020-03-05
EP3973982A1 (en) 2022-03-30
RS62810B1 (sr) 2022-02-28
BR112020003379A2 (pt) 2020-08-25
CN120617484A (zh) 2025-09-12
IL272763B2 (en) 2024-02-01
PH12020500404A1 (en) 2021-03-01
MY200791A (en) 2024-01-16
EP4427806A3 (en) 2024-10-09
ES2989511T3 (es) 2024-11-26
DK3973982T3 (da) 2024-09-23
JP6856819B2 (ja) 2021-04-14
CA3073624A1 (en) 2019-03-07
HRP20211802T1 (hr) 2022-03-04
UA126869C2 (uk) 2023-02-15
JOP20200034B1 (ar) 2024-04-18
EP3675894A1 (en) 2020-07-08
CN111050787A (zh) 2020-04-21
HUE068024T2 (hu) 2024-12-28
AU2018326556B2 (en) 2024-09-26
WO2019043143A1 (en) 2019-03-07
EP4427806A2 (en) 2024-09-11
KR20250078595A (ko) 2025-06-02
SG11202003840QA (en) 2020-05-28
PL3973982T3 (pl) 2024-11-04
MA50034B1 (fr) 2022-02-28
LT3973982T (lt) 2024-09-10
JP2020528071A (ja) 2020-09-17
EP3675894B1 (en) 2021-11-03
PT3973982T (pt) 2024-09-16
IL272763A (en) 2020-04-30

Similar Documents

Publication Publication Date Title
CL2018000947S1 (es) Automóvil
CL2018002782A1 (es) Apósito modificado
GEP20227403B (en) Compounds
GEP20217239B (en) Pharmaceutical composition
JOP20200300A1 (ar) أجسام مضادة لـ il-11ra
GEAP202114450A (en) Anti-tigit antibodies
MX375352B (es) Reguladores de nrf2.
CL2018001940S1 (es) Automóvil
DK3787667T3 (da) Sammensætning til kontrolleret ovariestimulation
GEP20217240B (en) Pharmaceutical composition
CL2018000791S1 (es) Automóvil
JOP20210036A1 (ar) مثبطات او- جليكوبروتين-2-أسيتاميدو-2-ديوكسي-3-دي-جلوكوبيرانوسيداز
JOP20200034A1 (ar) تركيبة للتنشيط المتحكم فيه للمبيض
JOP20210025A1 (ar) تركيبات وطرق للتنشيط المتحكم فيه للمبيض
CL2018000941A1 (es) Regulación del uso de nitrógeno
JOP20200318A1 (ar) عوامل تثبيط ask1
JOP20200108A1 (ar) توليفات شحمية
SE1600345A1 (sv) Counter mass
CL2018003471S1 (es) Envase
CL2018003472S1 (es) Envase
ECSDI18090902S (es) Tobogan clasico
CL2018002005S1 (es) Automóvil
HK40021791A (en) Composition for controlled ovarian stimulation
GEAP201814364A (en) Radial-squeezing machine
GEAP201814402A (en) Method for cement production